Proposal for a regulation on health technology assessment in Europe – opinions of policy makers, payers and academics from the field of HTA-Reference-Cited by-同舟云学术

Proposal for a regulation on health technology assessment in Europe – opinions of policy makers, payers and academics from the field of HTA

Published:2019-02-15 Issue:3 Volume:19 Page:251-261
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Vella Bonanno Patricia¹,Bucsics Anna²,Simoens Steven³,Martin Antony P⁴,Oortwijn Wija⁵,Gulbinovič Jolanta⁶,Rothe Celia⁷,Timoney Angela¹⁸,Ferrario Alessandra⁹,Gad Mohamed¹⁰,Salem Ahmed¹¹,Hoxha Iris¹²,Sauermann Robert¹³,Kamusheva Maria¹⁴^ORCID,Dimitrova Maria¹⁴,Petrova Guenka¹⁴,Laius Ott¹⁵,Selke Gisbert¹⁶,Kourafalos Vasilios¹⁷,Yfantopoulos John¹⁸^ORCID,Magnusson Einar¹⁹,Joppi Roberta²⁰,Jakupi Arianit²¹,Bochenek Tomasz⁷,Wladysiuk Magdalene²²,Furtado Claudia²³,Marković-Peković Vanda²⁴²⁵,Mardare Ileana²⁶,Meshkov Dmitry²⁷,Fürst Jurij²⁸,Tomek Dominik²⁹,Cortadellas Merce Obach³⁰,Zara Corrine³⁰,Haycox Alan⁴,Campbell Stephen³¹³²,Godman Brian¹⁴³³³⁴^ORCID

Affiliation:

1. Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK

2. Mechanism of Coordinated Access to Orphan Medicinal Products (MoCA), Brussels, Belgium

3. KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium

4. Health Economics Centre, University of Liverpool Management School, Liverpool, UK

5. Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands

6. Department of Pathology, Forensic Medicine and Pharmacology, Institute of Biomedical Sciences, Faculty of Medicine, VilniusUniversity, Vilnius, Lithuania

7. Department of Drug Management, Faculty of Health Sciences, Jagiellonian University Medical College, Krakow, Poland

8. NHS Lothian, Edinburgh, UK

9. Division of Health Policy and Insurance Research, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA

10. Global Health and Development Group, Imperial College, London, UK

11. IQVIA, Brussels, Belgium

12. Department of Pharmacy, Faculty of Medicine, University of Medicine, Tirana, Albania

13. Hauptverband der ÖsterreichischenSozialversicherungsträger, Vienna, Austria

14. Department of Organization and Economics of Pharmacy, Faculty of Pharmacy, Medical University-Sofia, Bulgaria

15. State Agency of Medicines, Tartu, Estonia

16. Wissenschaftliches Institut der AOK (WidO), Berlin, Germany

17. EOPYY-National Organization for the Provision of Healthcare Services, Athens, Greece

18. School of Economics and Political Science, University of Athens, Athens, Greece

19. Department of Health Services, Ministry of Health, Reykjavík, Iceland

20. Pharmaceutical Drug Department, Azienda Sanitaria Locale of Verona, Verona, Italy

21. UBT - Higher Education Institute, Prishtina, Kosovo

22. HTA Consulting, Cracow, Poland

23. Pharmaceutical Division, INFAMED, Lisbon, Portugal

24. Ministry of Health and Social Welfare, Banja Luka, Republic of Srpska, Bosnia and Herzegovina

25. Department of Social Pharmacy, University of Banja Luka, Faculty of Medicine, Banja Luka, Republic of Srpska, Bosnia and Herzegovina

26. Faculty of Medicine, Public Health and Management Department, “Carol Davila” University of Medicine and Pharmacy Bucharest, Bucharest, Romania

27. National Research Institution for Public Health, Moscow, Russia

28. Health Insurance Institute, Ljubljana, Slovenia

29. Faculty of Medicine, Slovak Medical University, Bratislava, Slovakia.

30. Drug Territorial Action Unit, Catalan Health Service, Barcelona, Spain

31. Centre for Primary Care, Division of Population Health, Health Services Research and Primary Care, University of Manchester, Manchester, UK

32. NIHR Greater Manchester Patient Safety Translational Research Centre, School of Health Sciences, University of Manchester, Manchester, UK

33. Division of Clinical Pharmacology, Karolinska, Karolinska Institutet, Stockholm, Sweden

34. Department of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Garankuwa, South Africa

Funder

paper

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2019.1575730

Reference98 articles.

1. MEDEV - Medicines evaluation committee; 2018. Available from: www.medev-com.eu

2. AIM. Association internationale de mutualite; 2018. Available from: https://www.aim-mutual.org/

3. ESIP - European social insurance platform. Available from: www.esip.eu

4. Vaisman E. ADOPTION OF THE ENVI REPORT ON HTA - ESIP welcomes a balanced approach to HTA at EU level; 2018. Available from: https://www.esip.eu/new/details/2/55-Adoption%20of%20the%20ENVI%20report%20on%20HTA

5. European Parliament. Draft Report on the proposal for a regulation of the European Parliament and of the Council on health technology assessment and amending Directive 2011/24/EU (COM(2018)0051 – C8-0024/2018/0018(COD)), Committee on the Environment, Public Heath and Food Safety; 2018. Available from: http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&reference=PE-622.011&format=PDF&language=EN&secondRef=01

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Opportunities and Challenges in Cross-Country Collaboration: Insights from the Beneluxa Initiative;Journal of Market Access & Health Policy;2024-07-09

2. Suitability of the Current Health Technology Assessment of Innovative Artificial Intelligence-Based Medical Devices: Scoping Literature Review;Journal of Medical Internet Research;2024-05-13

3. Suitability of the Current Health Technology Assessment of Innovative Artificial Intelligence-Based Medical Devices: Scoping Literature Review (Preprint);2023-08-02

4. The role of stakeholder involvement in the evolving EU HTA process: Insights generated through the European Access Academy’s multi-stakeholder pre-convention questionnaire;Journal of Market Access & Health Policy;2023-06-04

5. The role of Iran's context for the development of health technology assessment: challenges and solutions;Health Economics Review;2023-04-20